Proactive Investors - Run By Investors For Investors

Allergy Therapeutics highlights benefits of adjuvant technology in new paper

The study highlighted Allergy’s microcrystalline tyrosine (MCT) was a suitable and flexible alternative to aluminium hydroxide
hay fever
MCT generates a faster response

Hay fever vaccine specialist Allergy Therapeutics PLC (LON:AGY) has published new data highlighting the effectiveness of its technology as an adjuvant compared to existing treatment.

An adjuvant stimulates the body’s immune response to an antigen and helps it react quicker to the threat.

WATCH: 'Pivotal' year ahead for Allergy Therapeutics with key trial readouts

The study highlighted Allergy’s microcrystalline tyrosine (MCT) was a suitable and flexible alternative to aluminium hydroxide in both allergen-specific immunotherapy and infectious disease applications. 

"These findings provide evidence of the effectiveness of MCT as an adjuvant, confirming the mechanism of action underlying its ability to induce a robust and sustained immunological response." said Matthias Kramer, Allergy Therapeutics' International Medical Director and co-author of the paper.

"We believe these data highlight the significance of our differentiated proprietary platform technology in the development of our growing suite of cutting-edge, globally marketed ultra-short course allergy vaccines."   

Studies in a cancer (melanoma) model are underway.

Allergy published the findings of its work online in the Journal of Immunology.

View full AGY profile View Profile

Allergy Therapeutics PLC Timeline

Related Articles

scientist with vial
September 25 2018
The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology
September 25 2018
A decision on whether or not Motif can start marketing its next-generation antibiotic in the US is due by mid-February
immunotherapy graphic
September 13 2018
A clinical trial application for the potential cancer treatment is on track to be filed in the current quarter, and that will be followed by patient recruitment towards the end of the year

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use